Skip to main content
. Author manuscript; available in PMC: 2023 Apr 1.
Published in final edited form as: Clin Gastroenterol Hepatol. 2021 May 29;20(4):766–775.e4. doi: 10.1016/j.cgh.2021.05.049

Table 1:

Patient characteristics.

Characteristics Median, IQR, or Frequency (%)
n=100
(All)
Median, IQR, or Frequency (%)
n=45
(Non-dilated group)
Median, IQR, or Frequency (%)
n=55
(Dilated group)
Age (years) at index endoscopy 37.4 (27 to 46) 32.6 (23.5 to 45.1) 38.4 (31.1 to 46.7)
Age (years) at diagnosis a 32.0 (22 to 41) 30.0 (19.0 to 39.0) 35.5 (28.0 to 41.0)
Age (years) at first endoscopy b 31.0 (20 to 39) 30.0 (19.5 to 41.0) 32.2 (24.0 to 39.0)
Age (years) at first symptom onset c 23.5 (15 to 34) 22.2 (16.0 to 38.0) 26.2 (12.6 to 33.8)
Disease duration (years) d 9.7 (4 to 19) 7.1 (3.8 to 12.4) 10.2 (7.1 to 22.7)
Diagnostic delay (years) e 4.0 (1 to 13) 3.0 (0.9 to 29.9) 8.9 (0.1 to 40.0)
Male 61 (61.0%) 25 (55.6%) 36 (65.5%)
White 94 (94.0%) 42 (93.3%) 52 (94.5%)
Peak eos/hpf 18.0 (2 to 51) 18.0 (2.0 to 48) 19.0 (2.0 to 52)
EoEHSS (grade+stage) 0.7 (0.3 to 0.9) 0.7 (0.3 to 0.9) 0.6 (0.3 to 1.0)
EREFS (proximal+distal) 5 (2 to 8) 3 (2 to 7) 5 (3 to 9)
EREFS (proximal) 2 (1 to 4) 2 (1 to 3) 3 (1 to 4)
EREFS (distal) 3 (1 to 5) 2 (1 to 3) 3 (2 to 5)
RS (proximal+distal) 2 (0 to 4) 1 (0 to 6) 3 (0 to 8)
RS (proximal) 1 (0 to 2) 1 (0 to 3) 1 (0 to 4)
RS (distal) 1 (0 to 2) 0 (0 to 3) 2 (0 to 4)
EEF (proximal+distal) 3 (1 to 4) 3 (0 to 8) 3 (0 to 8)
EEF (proximal) 1 (0 to 2) 1 (0 to 3) 1 (0 to 4)
EEF (distal) 2 (0 to 3) 1 (0 to 5) 2 (0 to 5)
EEsAI PRO score 27 (12 to 42) 27 (12 to 43) 27 (12 to 39)
Frequency of trouble swallowing
Never 43 (43.0%) 18 (40.0%) 25 (45.5%)
1–3 times/week 39 (39.0%) 17 (37.8%) 22 (40.0%)
4–6 times/week 13 (13.0%) 6 (13.3%) 7 (12.7%)
Daily 5 (5.0%) 4 (8.9%) 1 (1.8%)
Pain when swallowing 17 (17.0%) 8 (17.8%) 9 (16.4%)
Visual dysphagia question 1.7 (0 to 6) 2.1 (0.4 to 3.3) 1.4 (0 to 3.3)
Avoidance, modification, slow eating (median (range)) 1.7 (0 to 6) 1.8 (0.3 to 3.2) 1.5 (0.5 to 2.9)
EoE-QoL-A score 27.0 (15 to 48) 27.0 (15.0 to 51.0) 26.5 (16.0 to 47.5)
Impact of diet/eating 6.0 (3 to 10) 7.0 (3.0 to 11.0) 5.0 (3.0 to 9.0)
Social impact 4.0 (1 to 8) 4.0 (1.0 to 8.0) 3.0 (0.0 to 8.0)
Emotional impact 7.0 (3 to 13) 7.0 (3.0 to 13.0) 7.0 (3.0 to 11.0)
Disease anxiety 6.0 (3 to 12) 6.0 (3.0 to 11.0) 7.0 (4.0 to 12.0)
Swallowing anxiety 4.0 (1 to 6) 4.0 (1.0 to 8.0) 4.0 (2.0 to 6.0)
Anti-eosinophil therapy (at index endoscopy)
None 4 (4.0%) 1 (2.2%) 3 (5.5%)
Monotherapy with diets 21 (21.0%) 11 (24.4%) 10 (18.2%)
Monotherapy with proton-pump inhibitors 11 (11.0%) 5 (11.1%) 6 (10.9%)
Monotherapy with swallowed topical corticosteroids 28 (28.0%) 14 (31.1%) 14 (25.5%)
Mixed treatments 36 (36.0%) 14 (31.1%) 22 (40.0%)
Dilation 55 NA 55
≤1 year prior index endoscopy 15 (15%) NA n=15
Median time (years) from dilation date to index endoscopy, IQR, range
0.59 (0.40 to 0.86), 0.11 to 0.996
>1 year prior to index endoscopy 40 (40%) NA n=40
Median time (years) from dilation date to index endoscopy, IQR, range
3.49 (1.95 to 4.11), 1.05 to 19.3
a

Data available in 39/45 non-dilated and 50/55 dilated patients.

b

Data available in 44/45 non-dilated and 53/55 dilated patients.

c

Data available in 38/45 non-dilated and 44/55 dilated patients.

d

The disease duration is defined as the time interval between the first symptom onset and index endoscopy (data available in 38/45 non-dilated and 44/55 dilated patients).

e

The diagnostic delay is defined as the time interval between the first symptom onset and diagnosis (data available in 32/45 non-dilated and 41/55 dilated patients).

Abbreviations: EEsAI, eosinophilic esophagitis activity index; eos/hpf, esophageal eosinophilia per high-power field; EoE-QoL-A, adult eosinophilic esophagitis-specific quality of life; EREFS, endoscopic reference score; IQR, interquartile range; RS, rings and stricture score.